Atanas Radinoff

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

Hematological Malignancy, Once-per-week Selinexor, Medicine +7

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti et al. · Leukemia · 2018 · 159 citations · Full text

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff et al. · The Lancet Haematology · 2023 · 113 citations

Hematological Malignancy, Oncology, Metronomic Therapy +10

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes, David M. Ross, Atanas Radinoff et al. · Leukemia · 2021 · 59 citations · Full text